Related Experiment Video
Updated: Apr 3, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells
Jesus F San Miguel1, Bruno Paiva1, Juan-Jose Lasarte1
1Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

